Actavis divesting two more assets ahead of Allergan takeover
This article was originally published in Scrip
Executive Summary
Actavis is selling two more assets – Aptalis Pharmaceutical Technologies (Pharmatech) and US rights to the acne drug Doryx – as the company prepares to take on a massive aesthetic and therapeutic portfolio when its $66bn acquisition of Irvine, California-based Allergan closes in a month or two.